Medical & Biological Laboratories, a Japanese drug development company, says it has purchased Bion Enterprises, an Illinois, USA-based virus reagent maker, through a US sales unit. The value of the deal was not disclosed, reports the JCNNetWork.
The acquisition will allow the Japanese firm to develop and sell its products in the USA. The company also hopes to expand its business in South American nations through the new base. The transaction is expected to raise M&BL group sales by 200.0 million yen ($1.9 milli0n) in the current business year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze